This is a basic overview course, intended for individuals who have limited experience in pharmacovigilance/drug safety monitoring. The focus will be on pharmacovigilance with traditional medicinal products, both investigational and marketed, intended for human use in clinical trials, in post-marketing studies, and in the healthcare setting following product launch.
Regional developments in the GCC countries will also be highlighted.
Gaby L. Danan, MD, PhD • Pharmacovigilance Expert
William W. Gregory, PhD • Senior Director, Worldwide Safety and Regulatory
Pfizer Inc, United States
Bina S. Patel • Director Case Management Group
GlaxoSmithKline R&D Ltd., United Kingdom
Harri Tapani Helajarvi • Former Qualified Person for Pharmacovigilance